FDA Closes 2013 With Flurry Of Citations For Misleading Rx Promotions
This article was originally published in The Pink Sheet Daily
Office of Prescription Drug Promotion issues 23 letters in 2013, five less than the previous year.
You may also be interested in...
OPDP Director Tom Abrams cautions against reading into the “snapshot.”
Justice Ginsburg wrote two decisions in pharmaceutical related-cases over the past decade, joined the majority in opinions on the scope of patents, and dissented in decisions giving protection to generic manufacturers and speech of pharmaceutical companies. Her death could impact the outcome of cases challenging the Affordable Care Act.
Neither has announced a firm timeline, and the difference between Pfizer's 'October' and Moderna's 'November' could be mere hours or a few weeks, but Pfizer, by dint of luck or experience, is now in a position to offer the more optimistic projection on when it will seek an EUA. Both firms release their Phase III trial protocols, which seem in line with US FDA guidance.